To hear about similar clinical trials, please enter your email below
Trial Title:
Tumor Microenvironment
NCT ID:
NCT05982574
Condition:
Lung Adenocarcinoma
Conditions: Official terms:
Adenocarcinoma
Adenocarcinoma of Lung
Study type:
Observational
Overall status:
Active, not recruiting
Study design:
Time perspective:
Retrospective
Summary:
Cancer immunotherapy has the great potential to achieve long-term survival in patients
with a solid malignancy. However, the beneficial effect of cancer immunotherapy is seen
in only a minority of patients. Mounting evidence suggests that immunosuppressive
features in the tumor microenvironment prevent an effective antitumor defense. The aim of
the investigators is to comprehensively analyze the cytokine profile and the tumor immune
infiltrate in the tumor microenvironment and to investigate its prognostic significance
in patients with radically resected lung adenocarcinoma.
Criteria for eligibility:
Study pop:
Patients with completely resected lung adenocarcinoma stage IB and II
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- Lung adenocarcinoma
- Tumor stage IB and II
- With or without adjuvant therapy
- Complete surgical resection (R0)
- No distant metastasis at the time of surgery (M0)
Exclusion Criteria:
• Second cancer within 5 years
Gender:
All
Minimum age:
18 Years
Maximum age:
90 Years
Healthy volunteers:
No
Start date:
February 2016
Completion date:
December 2026
Lead sponsor:
Agency:
University Hospital Heidelberg
Agency class:
Other
Source:
University Hospital Heidelberg
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05982574
